Echinocandins and the 2009 guidelines for treatment of candidiasis
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved..
Candida is the most frequent cause of invasive fungal infections in humans that yield high levels of mortality and health-related costs. Several factors lead to the development of candidemia. The Infectious Diseases Society of America (IDSA) updated its guidelines for the management of candidiasis and proper use of antifungal agents in Candida infections. The echinocandins are novel antifungal 1,3-beta-glucan synthase inhibitors and are currently the first choice treatment for most Candida infections, with good responses to support its use.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 Suppl B |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 46 Suppl B(2010) vom: 15. März, Seite 7-12 |
| Sprache: |
Portugiesisch |
|---|
| Weiterer Titel: |
Equinocandinas e as diretrizes de 2009 para tratamento da candidíase |
|---|
| Beteiligte Personen: |
Melo, Luis Henrique [VerfasserIn] |
|---|
| Themen: |
1,3-beta-glucan synthase |
|---|
| Anmerkungen: |
Date Completed 07.06.2010 Date Revised 27.04.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM197496865 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM197496865 | ||
| 003 | DE-627 | ||
| 005 | 20231223210701.0 | ||
| 007 | tu | ||
| 008 | 231223s2010 xx ||||| 00| ||por c | ||
| 028 | 5 | 2 | |a pubmed24n0658.xml |
| 035 | |a (DE-627)NLM197496865 | ||
| 035 | |a (NLM)20407663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a por | ||
| 100 | 1 | |a Melo, Luis Henrique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Echinocandins and the 2009 guidelines for treatment of candidiasis |
| 246 | 3 | 3 | |a Equinocandinas e as diretrizes de 2009 para tratamento da candidíase |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2010 | ||
| 500 | |a Date Revised 27.04.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved. | ||
| 520 | |a Candida is the most frequent cause of invasive fungal infections in humans that yield high levels of mortality and health-related costs. Several factors lead to the development of candidemia. The Infectious Diseases Society of America (IDSA) updated its guidelines for the management of candidiasis and proper use of antifungal agents in Candida infections. The echinocandins are novel antifungal 1,3-beta-glucan synthase inhibitors and are currently the first choice treatment for most Candida infections, with good responses to support its use | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Glucosyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 650 | 7 | |a 1,3-beta-glucan synthase |2 NLM | |
| 650 | 7 | |a EC 2.4.1.34 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 46 Suppl B(2010) vom: 15. März, Seite 7-12 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:46 Suppl B |g year:2010 |g day:15 |g month:03 |g pages:7-12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 Suppl B |j 2010 |b 15 |c 03 |h 7-12 | ||